6533b7dafe1ef96bd126ecb2
RESEARCH PRODUCT
Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?
Manuela LabbozzettaGiovanni VizziniNatale D'alessandroMonica NotarbartoloPaola PomaAlessio ProvenzaniPiera Polidorisubject
DrugUGT1A4Genotypemedia_common.quotation_subjectMultiple Organ FailurePharmaceutical ScienceSNPPharmacyLamotrigineToxicologyLamotriginePolymorphism Single NucleotideVasoactiveRashmedicineHumansPharmacology (medical)GlucuronosyltransferaseUGT2B7media_commonPharmacologybusiness.industryTriazinesPharmacogeneticMultiorgan dysfunctionABCB1ExanthemaRashHLAMulti-organ dysfunctionAnesthesiaBreathingSettore BIO/14 - FarmacologiaAnticonvulsantsFemaleUGT1A4medicine.symptombusinessPharmacogeneticsAntiepileptic drugmedicine.drugdescription
We report the case of a 38-year-old woman treated with lamotrigine who experienced multi-organ dysfunction. The patient received the drug at the dose of 100 mg per day. One week later, the treatment was suspended because of an extensive body rash. Twenty-four hours later, the patient appeared drowsy and stuporous and was hospitalized. On the fifth day, the patient was admitted with a clinical picture of acute multi-organ failure in our Institute, where, she, despite the support of vital functions with vasoactive drugs, continuous hemofiltration and ventilation with oxygen, died. Serum lamotrigine concentration was measured 110 h after its last dose and the drug resulted to be still present at 1 mg/L. The patient was homozygous for the UGT1A4-70C and UGT2B7-161C alleles and heterozygous for the UGT2B7-372AG polymorphism. Regarding ABCB1 the patient showed the 3435CC, 2677GT and 1236CT genotypes.Our results may suggest a role of the UGT2B7-372AG polymorphism in this reaction.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-27 |